Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
17 participants
INTERVENTIONAL
2002-04-30
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perimenopausal Effects of Estradiol on Reward Responsiveness
NCT02255175
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
NCT03505905
Perimenopause-Related Mood and Behavioral Disorders
NCT00001231
Estrogen Variability and Irritability During the Menopause Transition
NCT05388656
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
NCT00626340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
0.625 mg/day of conjugated estrogen
Estrogen
0.625 mg/day of conjugated Estrogen
Placebo
Daily placebo for conjugated estrogen
Estrogen
0.625 mg/day of conjugated Estrogen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estrogen
0.625 mg/day of conjugated Estrogen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HAM-D between 10 and 17
Exclusion Criteria
* Current substance abuse
40 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Alliance for Research on Schizophrenia and Depression
OTHER
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melinda L. Morgan, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Neuropsychiatric Institute & Hospital
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry. 2005 Jun;66(6):774-80. doi: 10.4088/jcp.v66n0617.
Cook IA, Morgan ML, Dunkin JJ, David S, Witte E, Lufkin R, Abrams M, Rosenberg S, Leuchter AF. Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study. Int J Geriatr Psychiatry. 2002 Jul;17(7):610-8. doi: 10.1002/gps.644.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06806-001
Identifier Type: -
Identifier Source: secondary_id
04-05-088
Identifier Type: -
Identifier Source: secondary_id
NARSAD06806-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.